Search NLS News

NextCell Pharma has formed a subsidiary company, QVance, specializing in quality control analytics. QVance, based in Huddinge, will specialize in quality analyses for advanced therapeutic companies, including NextCell, in the growing cell and gene therapy market. “It will address a large gap in the Nordic region, where there is a significant lack of local providers […]

The appointment of Uwe Gottschalk follows the resignation of Mats Leifland, who served as Chairman of the Board until March 12, 2024. “Uwe Gottschalk’s appointment as new Chairman marks a major milestone for Cellevate. With his extensive industry knowledge, decades of experience, and invaluable network connections, Dr. Uwe Gottschalk is well-suited to lead Cellevate into […]

The funds will be used to support development of Asgard’s lead program AT-108 to IND-readiness by 2026, expand and reinforce its research and development team, and fuel new reprogramming modalities and delivery platforms to strengthen the pipeline. “Asgard’s technology overcomes challenges faced by traditional cell therapies, enabling the recreation of desired functional immune cells directly […]

Anocca and EmendoBio have announced a non-exclusive licensing agreement for the use of EmendoBio’s novel OMNI-A4 nuclease to accelerate the manufacture and development of Anocca’s deep pipeline of TCR-T cell therapies for difficult-to-treat solid cancers. “Integrating EmendoBio’s nuclease into our manufacturing process supports Anocca’s aim of generating the highest-quality cell therapy products. This next-generation gene […]

Atrogi has announced the full set of results from its Phase 1 a/b trial with ATR-258, its first-in-class treatment for type 2 diabetes (T2D). “This full phase 1a/b data readout is exactly what we were aiming for, with primary and secondary safety-endpoints met. This puts us in a strong position to progress our ground-breaking small […]

AstraZeneca has entered into a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases. Under the terms of the agreement, AstraZeneca will acquire all of Amolyt Pharma’s outstanding shares for a total consideration of up to USD 1.05 billion, on a cash and debt free […]

Professor Anna Martling has been appointed Scientific Director Life Science at Karolinska Institutet (KI). This is a new mission at KI, which involves coordinating internal initiatives and representing KI externally in the field. One of its main arenas of concern is the KI-Region Stockholm collaboration organisation. KI’s Strategy 2030 emphasises KI’s commitment to being an […]

On February 20th, SwedenBIO and Cencora PharmaLex organized a Brain & Breakfast event in Stockholm about the EU HTA process and challenges and opportunities for implementation in Sweden. During a 60 minute discussion, participants delved into the current landscape of the Joint Clinical Assessment (JCA), both from a European and Swedish perspective, offering insights from […]

The FDA has approved a label expansion for Wegovy based on a supplemental New Drug Application for the indication of reducing risks of major adverse cardiovascular events including cardiovascular death, non-fatal heart attack (myocardial infarction) or non-fatal stroke in adults with either overweight or obesity and established cardiovascular disease. The approval is based on the […]

In November 2023 SynAct Pharma reported that during the evaluation of the data from part A of the RESOLVE study, a four-week dose range study of resomelagon (AP1189) in rheumatoid arthritis patients with an inadequate response to methotrexate treatment, issues were identified that needed further evaluation and initiated an audit of the study by an […]